Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 7/20 | 0.38 |
| ▸ | MMP13 | P45452 | 7/20 | 0.38 |
| ▸ | MMP2 | P08253 | 5/20 | 0.38 |
| ▸ | MMP14 | P50281 | 2/20 | 0.38 |
| ▸ | BMP1 | P13497 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 5/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880329 | 0.91 | MMP13 (0.39) | MMP9MMP13MMP2MMP14BMP1 | |
| SCHEMBL3878923 | 0.81 | MMP9 (0.41) | MMP9MMP13MMP2MMP14BMP1 | |
| SCHEMBL3870206 | 0.79 | ALDH1A1 (0.43) | MMP9MMP13MMP2MMP14MMP1 | |
| SCHEMBL1800363 | 0.79 | MEN1 (0.37) | MMP9MMP13MMP2MMP14BMP1 | |
| SCHEMBL7249318 | 0.78 | ADAM17 (0.63) | MMP9MMP13MMP2MMP14MMP1 | |
| SCHEMBL3878903 | 0.73 | ALDH1A1 (0.42) | MMP9MMP13MMP2MMP14MMP1 | |
| SCHEMBL4299834 | 0.73 | TACR2 (0.42) | MMP9MMP13MMP2MMP14SCN9A | |
| SCHEMBL1797411 | 0.71 | ADAMTS7 (0.49) | MMP9MMP13MMP2MMP14MMP1 | |
| SCHEMBL1797412 | 0.71 | ADAMTS7 (0.49) | MMP9MMP13MMP2MMP14MMP1 | |
| SCHEMBL1800796 | 0.71 | MMP1 (0.48) | MMP9MMP13MMP2MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143386-A1 | Human adam-10 inhibitors | EXELIXIS, INC. | 2009-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143386-A1 | Human adam-10 inhibitors | ADAM10, ADAM12, CASP10 | MMP9 82/4885MMP13 97/4885MMP2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.